phase 3
study 3
safety 1
pharmacokinetics 1
pharmacodynamics 1
combination 2
therapy 4
refametinib 1
plus 1
sorafenib 1
patients 2
advanced 3
cancer 7
genetics 2
biology 1
pancreatic 3
ductal 1
adenocarcinoma 1
mk 1
allosteric 1
inhibitor 1
akt 1
secondline 1
gastric 1
gastroesophageal 1
junction 1
swog 1
cooperative 1
group 1
trial 1
s 1
mutant 1
idh 1
inhibits 1
hnf 1
block 1
hepatocyte 1
differentiation 1
promote 1
biliary 4
ii 1
gemcitabine 1
oxaliplatin 2
panitumumab 1
kras 1
wildtype 1
unresectable 2
metastatic 2
tract 3
gallbladder 1
plac 1
links 1
oncogenic 1
mutations 1
regulation 1
autophagy 2
critical 1
progression 1
stereotactic 2
body 1
radiation 2
bridge 2
transplantation 3
recurrent 1
disease 2
transplanted 1
liver 1
patient 1
hepatocellular 4
carcinoma 4
emerging 2
treatment 2
options 1
diabetes 2
mellitus 2
impacts 1
risk 1
macrovascular 1
invasion 1
undergoing 1
locally 1
neoadjuvant 1
leucovorin 1
fluorouracil 1
irinotecan 1
assessment 1
surgical 1
resectability 1
associated 1
presence 1
spread 1
presentation 1
intrahepatic 2
cholangiocarcinoma 2
krasgd 1
p 1
mutation 1
cause 1
primary 1
hypofractionated 1
clinical 1
outcome 1
pathologic 1
correlation 1
cancers 1
targeted 1
therapies 1
